Combined periorbital rejuvenation with P(LA-CL) threads & polynucleotides

Objectifs: To assess the efficacy and safety of a multimodal regenerative protocol combining biostimulatory threads and polynucleotide injections for the treatment of periorbital aging in a European patient population. Introduction: The periorbital area presents a therapeutic challenge owing to its thin skin, complex anatomy, and early manifestation of age-related changes. As regenerative aesthetics continues to evolve, combination therapies aimed at restoring tissue architecture and improving skin quality have gained increasing attention. A multimodal approach combining PLLA/PCL threads and polynucleotide injections may provide synergistic benefits and improve clinical outcomes. Matériels / méthode: A prospective study enrolled 18 patients (mean age 39 years) with mild-to-moderate periorbital aging. Treatment consisted of ten PLLA/PCL monofilament threads implanted in parallel within the superficial infraorbital plane, followed by intradermal injection of 0.5 mL polynucleotides per side. Clinical improvement, wrinkle severity, skin quality, patient satisfaction, and safety were assessed by both physicians and participants at baseline and after 1, 3, and 6 months follow-up visits. Standardized photographic assessments were performed throughout the study period. Résultats: A total of 18 patients completed the study. Progressive improvement in periorbital skin quality, wrinkles, and overall appearance was observed throughout follow-up. At 6 months, 16/18 patients (88.9%) achieved a rating of “much improved” or “very much improved” on the Global Aesthetic Improvement Scale (GAIS). Patient satisfaction was high, with 17/18 participants (94.4%) reporting satisfaction with treatment outcomes. Standardized photographic assessments confirmed sustained improvement. Mild transient oedema and ecchymosis resolved spontaneously. No serious adverse events were reported. Conclusion: The combined use of PLLA/PCL biostimulatory threads and polynucleotide injections demonstrated favorable efficacy and safety for periorbital rejuvenation. High levels of clinical improvement and patient satisfaction were observed, supporting this multimodal regenerative approach as a promising minimally invasive treatment option. Further prospective studies with larger cohorts and longer follow-up are warranted.